Metropolis Healthcare Limited announced its unaudited consolidated financial results for the quarter ended September 30, 2026, pursuant to Regulation 30 of SEBI Listing Regulations.

Financial Performance Highlights

Quarterly Performance (Q2 FY27 vs Q2 FY26):

  • Revenue from Operations: ₹496.8 crore, up 15.8% from ₹429.2 crore
  • Reported EBITDA: ₹134.9 crore, up 23.9% from ₹108.9 crore
  • Reported EBITDA Margin: 27.2%, improved by 180 basis points from 25.4%
  • Profit Before Tax (PBT): ₹102.5 crore, up 44.4% from ₹71.0 crore
  • Profit After Tax (PAT): ₹75.5 crore, up 42.7% from ₹52.9 crore
  • PAT Margin: 15.2%, improved by 290 basis points from 12.3%

Half-Yearly Performance (H1 FY27 vs H1 FY26):

  • Revenue from Operations: ₹947.0 crore, up 16.2% from ₹815.3 crore
  • Reported EBITDA: ₹248.2 crore, up 25.3% from ₹198.0 crore
  • Reported EBITDA Margin: 26.2%, improved by 190 basis points from 24.3%
  • Profit Before Tax (PBT): ₹180.2 crore, up 36.2% from ₹132.3 crore
  • Profit After Tax (PAT): ₹132.4 crore, up 34.9% from ₹98.1 crore
  • PAT Margin: 14.0%, improved by 200 basis points from 12.0%

Operational Highlights

  • Patient volume grew 10% YoY to 4.1 million patients
  • Test volume increased 11% YoY to 8.7 million tests
  • B2C revenue grew 17% YoY to ₹289 crore
  • B2B revenue rose 15% YoY to ₹208 crore
  • TruHealth revenue grew 20% YoY to ₹86 crore
  • Specialty revenue rose 20% YoY to ₹198 crore
  • Revenue per Patient (RPP) increased 6% YoY to ₹1,221
  • Revenue per Test (RPT) improved 5% YoY to ₹572
  • Tier III cities remained the fastest-growing markets with revenue rising around 20% YoY
  • Network expansion: 5,119 service points across approximately 750 towns

Corporate Action

The Board declared an interim dividend of ₹1 per share.

Management Commentary

Ms. Ameera Shah, Promoter and Executive Chairperson: Emphasized the company's H1FY27 performance with 16% revenue growth without price increases, reflecting patient and clinician trust. The company is building a stronger, differentiated platform focusing on science and genomics expertise, technology transformation, and strategic acquisitions. New offerings include a 1,000-gene oncology panel and blood-based Alzheimer's test.

Mr. Surendran Chemmenkotil, Managing Director: Highlighted the strong Q2 performance with 24% EBITDA growth and 180 bps margin expansion. For the rest of the year, the company will extend presence in Tier II and III towns, scale wellness and specialty portfolio, and broaden engagement with doctors and hospitals while maintaining disciplined execution.

Company Background

Established in 1981, Metropolis Healthcare is a leading diagnostic chain with over four decades of excellence. The company operates 213 laboratories with over 5,119 service points and 10,000+ touchpoints across 28 states, 7 Union Territories, and 750+ towns in India and Africa. Offers over 4,500 tests and profiles with consistent CAP proficiency score of over 99.99% for the past decade.